Hassaan Bashir, MD
Neurology · Lawrence, MANPI 1255774162
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 62.1% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $4,374, 7.9 times the $555 reported in 2019.
Across 91 payments — averaging $72.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Boston Scientific$1K
- Medtronic$319
- Teva Pharmaceuticals USA, Inc.$146
- Lilly USA, LLC$85
- Acorda Therapeutics, Inc$59
- plus $442 from 13 others
What the payments were for
- Speaking & faculty fees$2,94745%
- Travel & lodging$1,24919%
- Food & beverage$2,40936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $4,104 |
| Boston Scientific | 4 | $1,450 |
| Medtronic(2 entities) | 5 | $319 |
| Teva Pharmaceuticals USA, Inc. | 3 | $146 |
| Lilly USA, LLC | 4 | $85 |
| Acorda Therapeutics, Inc | 3 | $59 |
| Avanir Pharmaceuticals, Inc. | 3 | $58 |
| Kyowa Kirin, Inc. | 4 | $53 |
| Biogen | 2 | $49 |
| Pfizer | 3 | $45 |
| Vertical Pharmaceuticals, LLC | 2 | $41 |
| Amgen | 1 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| SK Life Science, Inc. | 1 | $27 |
| EMD Serono, Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| UCB, Inc. | 1 | $24 |
| GE HealthCare | 1 | $20 |
| Abbott | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$3,003
- VERCISE$1,450
- PERCEPT PC BRAINSENSE$127
- AUSTEDO$109
How this compares
$6,605 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 21 | $125,483 |
| RytaryCarbidopa/Levodopa | 59 | $75,650 |
| BotoxOnabotulinumtoxina | 55 | $67,871 |
| UbrelvyUbrogepant | 49 | $52,990 |
| Nurtec OdtRimegepant Sulfate | 24 | $44,086 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $38,042 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 833 | $31,080 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $24,816 |
| QuliptaAtogepant | 13 | $13,795 |
| Ajovy SyringeFremanezumab-Vfrm | 11 | $7,970 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,370 |
| Primidone | 125 | $6,368 |
| Levetiracetam | 173 | $6,019 |
| Rivastigmine | 22 | $5,423 |
| Gabapentin | 302 | $5,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta | $4,104 | $134,657117 claims |
| Amneal Pharmaceuticals LLCRytary | $28 | $75,65059 claims |
| PfizerNurtec Odt | $45 | $44,08624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 761 neurology providers in Massachusetts.
Other neurology in Lawrence
- Vladan MilosavljevicLawrence$129K
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
- Pushpa NarayanaswamiBoston$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.